{"id":512810,"date":"2021-07-14T07:25:08","date_gmt":"2021-07-14T11:25:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-i-iia-clinical-trial-combination-study-in-advanced-breast-cancer-patients-open-for-enrollment\/"},"modified":"2021-07-14T07:25:08","modified_gmt":"2021-07-14T11:25:08","slug":"briacell-phase-i-iia-clinical-trial-combination-study-in-advanced-breast-cancer-patients-open-for-enrollment","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-i-iia-clinical-trial-combination-study-in-advanced-breast-cancer-patients-open-for-enrollment\/","title":{"rendered":"BriaCell Phase I\/IIa Clinical Trial Combination Study in Advanced Breast Cancer Patients Open for Enrollment"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK and VANCOUVER, British Columbia, July  14, 2021  (GLOBE NEWSWIRE) &#8212; <strong>BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d)<\/strong>, a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, today announces the open recruitment and enrollment of their collaborative clinical study with Incyte. The Phase I\/IIa combination study is designed to evaluate BriaCell\u2019s lead candidate, Bria-IMT\u2122, with Incyte\u2019s checkpoint inhibitor, retifanlimab, and IDO1 inhibitor, epacadostat, for the treatment of advanced breast cancer.<\/p>\n<p align=\"justify\">The BriaCell and Incyte clinical program is a non-exclusive clinical trial collaboration to evaluate the effects of combinations of novel clinical candidates. Under the agreement, Incyte is providing compounds from its development portfolio, including retifanlimab, an anti-PD-1 monoclonal antibody, and epacadostat, an IDO1 inhibitor, for use in combination studies with Bria-IMT\u2122, in advanced breast cancer patients.<\/p>\n<p align=\"justify\">BriaCell and Incyte had previously treated two patients under this Phase I\/IIa combination study subsequent to the corporate collaboration <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bNDUsv-TzH-mhkBT-pcFjtl2QcOfgJ4ChxuVmQOFYy0pl_Wc3aWUTnCdiRye28f_154rkrwg4fcpPItybxwfPLfoRVQG2zgAXxkv2iHhAmo3wrPYag1iTbKsBbBEpCEjvZaEqDerBSFd0pqNy-KuJA==\" rel=\"nofollow noopener\" target=\"_blank\">commencement in April 2019<\/a>. Some of those patients were included in BriaCell\u2019s recent survival data announcement. With funding now secured, BriaCell has once again opened this collaborative study to enrollment.<\/p>\n<p align=\"justify\">\u201cWe are aligned with our clinical collaboration partners at Incyte in placing value on innovation and look forward to further developing novel therapeutics for advanced breast cancer patients together,\u201d stated Dr. Bill Williams, BriaCell\u2019s President and CEO. \u201cOur preliminary data indicates that this novel combination has the potential to be a safe and effective treatment for advanced breast cancer patients who have few to no other treatment options.\u201d<\/p>\n<p align=\"justify\">\n        <strong>About BriaCell Therapeutics Corp.<\/strong>\n      <\/p>\n<p align=\"justify\">BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uo1gdcITFP0OTU4R7p_5fDo4-eVNJ6q6m6Sicx8dI7ME-7sgclMKiRhxw3qAFih_8oDSOWdFkVTaXv9AI9KF7A==\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/briacell.com\/<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Safe Harbor<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d &#8220;will\u201d \u201cwould,\u201d or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BriaCell\u2019s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading &#8220;Risks and Uncertainties&#8221; in the Company&#8217;s most recent Management\u2019s Discussion and Analysis, under \u201cRisks and Uncertainties\u201d in the Company&#8217;s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under our profiles on SEDAR at www.sedar.com and on EDGAR at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5Zaa-K0iVaoIKC8raWhGbOW885fkI89MsuHvdoJ9ifJhN5h0YdhGW7fu3BjQiKIgG9_qwahagjPyKcCOaOB_2Q==\" rel=\"nofollow noopener\" target=\"_blank\"><strong>www.sec.gov<\/strong><\/a>. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.<\/p>\n<p align=\"justify\">Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/p>\n<p>\n        <strong>Contact Information<\/strong>\n      <\/p>\n<p>\n        <strong>Company Contact:<\/strong><br \/>\n        <br \/>William V. Williams, MD<br \/>President &amp; CEO<br \/>1-888-485-6340<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PsAsaru8EIJgeRGiCVhxyv0cHQO36lRqhWBJtYp4X-rVPVtlk1EMG7WNFXQGGqU0saBpjxf3JZpGt_EN8Sc-8w==\" rel=\"nofollow noopener\" target=\"_blank\">info@briacell.com<\/a><\/p>\n<p>\n        <strong>Media Relations:<\/strong><br \/>\n        <br \/>Jules Abraham<br \/>Director of Public Relations<br \/>CORE IR<br \/>917-885-7378<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zouQluhOLMXjhzXEKwBhNgCuVr-WCMfkPfgr8ifp71L9gk4W-avxamEQHLCOr61xEnL_IA_Bke_OHE5pXygqUg==\" rel=\"nofollow noopener\" target=\"_blank\">julesa@coreir.com<\/a>\u00a0<\/p>\n<p>\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>CORE IR<br \/><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=R54ZpHXm4HxJmKOxX8CyzlU09Y_FancWdSqX94EgWnVCzOU8Fx2iUjNhiWp_pMP74qcBf6YfM45PUE6H5rOWmT4fQR8vXlG3VpAageFeubE=\" rel=\"nofollow noopener\" target=\"_blank\">investors@briacell.com<\/a><\/u><\/p>\n<p>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MDAyOCM0Mjk2MDQ4IzIwOTA2NTg=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/17e4caf2-f6cb-44c0-8ff2-d20f7c050eed\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK and VANCOUVER, British Columbia, July 14, 2021 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, today announces the open recruitment and enrollment of their collaborative clinical study with Incyte. The Phase I\/IIa combination study is designed to evaluate BriaCell\u2019s lead candidate, Bria-IMT\u2122, with Incyte\u2019s checkpoint inhibitor, retifanlimab, and IDO1 inhibitor, epacadostat, for the treatment of advanced breast cancer. The BriaCell and Incyte clinical program is a non-exclusive clinical trial collaboration to evaluate the effects of combinations of novel clinical candidates. Under the agreement, Incyte is providing compounds from its development portfolio, including retifanlimab, an anti-PD-1 monoclonal antibody, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-i-iia-clinical-trial-combination-study-in-advanced-breast-cancer-patients-open-for-enrollment\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BriaCell Phase I\/IIa Clinical Trial Combination Study in Advanced Breast Cancer Patients Open for Enrollment&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-512810","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BriaCell Phase I\/IIa Clinical Trial Combination Study in Advanced Breast Cancer Patients Open for Enrollment - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-i-iia-clinical-trial-combination-study-in-advanced-breast-cancer-patients-open-for-enrollment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BriaCell Phase I\/IIa Clinical Trial Combination Study in Advanced Breast Cancer Patients Open for Enrollment - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK and VANCOUVER, British Columbia, July 14, 2021 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, today announces the open recruitment and enrollment of their collaborative clinical study with Incyte. The Phase I\/IIa combination study is designed to evaluate BriaCell\u2019s lead candidate, Bria-IMT\u2122, with Incyte\u2019s checkpoint inhibitor, retifanlimab, and IDO1 inhibitor, epacadostat, for the treatment of advanced breast cancer. The BriaCell and Incyte clinical program is a non-exclusive clinical trial collaboration to evaluate the effects of combinations of novel clinical candidates. Under the agreement, Incyte is providing compounds from its development portfolio, including retifanlimab, an anti-PD-1 monoclonal antibody, &hellip; Continue reading &quot;BriaCell Phase I\/IIa Clinical Trial Combination Study in Advanced Breast Cancer Patients Open for Enrollment&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-i-iia-clinical-trial-combination-study-in-advanced-breast-cancer-patients-open-for-enrollment\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-14T11:25:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MDAyOCM0Mjk2MDQ4IzIwOTA2NTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-phase-i-iia-clinical-trial-combination-study-in-advanced-breast-cancer-patients-open-for-enrollment\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-phase-i-iia-clinical-trial-combination-study-in-advanced-breast-cancer-patients-open-for-enrollment\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BriaCell Phase I\\\/IIa Clinical Trial Combination Study in Advanced Breast Cancer Patients Open for Enrollment\",\"datePublished\":\"2021-07-14T11:25:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-phase-i-iia-clinical-trial-combination-study-in-advanced-breast-cancer-patients-open-for-enrollment\\\/\"},\"wordCount\":599,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-phase-i-iia-clinical-trial-combination-study-in-advanced-breast-cancer-patients-open-for-enrollment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4MDAyOCM0Mjk2MDQ4IzIwOTA2NTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-phase-i-iia-clinical-trial-combination-study-in-advanced-breast-cancer-patients-open-for-enrollment\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-phase-i-iia-clinical-trial-combination-study-in-advanced-breast-cancer-patients-open-for-enrollment\\\/\",\"name\":\"BriaCell Phase I\\\/IIa Clinical Trial Combination Study in Advanced Breast Cancer Patients Open for Enrollment - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-phase-i-iia-clinical-trial-combination-study-in-advanced-breast-cancer-patients-open-for-enrollment\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-phase-i-iia-clinical-trial-combination-study-in-advanced-breast-cancer-patients-open-for-enrollment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4MDAyOCM0Mjk2MDQ4IzIwOTA2NTg=\",\"datePublished\":\"2021-07-14T11:25:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-phase-i-iia-clinical-trial-combination-study-in-advanced-breast-cancer-patients-open-for-enrollment\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-phase-i-iia-clinical-trial-combination-study-in-advanced-breast-cancer-patients-open-for-enrollment\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-phase-i-iia-clinical-trial-combination-study-in-advanced-breast-cancer-patients-open-for-enrollment\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4MDAyOCM0Mjk2MDQ4IzIwOTA2NTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4MDAyOCM0Mjk2MDQ4IzIwOTA2NTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-phase-i-iia-clinical-trial-combination-study-in-advanced-breast-cancer-patients-open-for-enrollment\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BriaCell Phase I\\\/IIa Clinical Trial Combination Study in Advanced Breast Cancer Patients Open for Enrollment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BriaCell Phase I\/IIa Clinical Trial Combination Study in Advanced Breast Cancer Patients Open for Enrollment - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-i-iia-clinical-trial-combination-study-in-advanced-breast-cancer-patients-open-for-enrollment\/","og_locale":"en_US","og_type":"article","og_title":"BriaCell Phase I\/IIa Clinical Trial Combination Study in Advanced Breast Cancer Patients Open for Enrollment - Market Newsdesk","og_description":"NEW YORK and VANCOUVER, British Columbia, July 14, 2021 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, today announces the open recruitment and enrollment of their collaborative clinical study with Incyte. The Phase I\/IIa combination study is designed to evaluate BriaCell\u2019s lead candidate, Bria-IMT\u2122, with Incyte\u2019s checkpoint inhibitor, retifanlimab, and IDO1 inhibitor, epacadostat, for the treatment of advanced breast cancer. The BriaCell and Incyte clinical program is a non-exclusive clinical trial collaboration to evaluate the effects of combinations of novel clinical candidates. Under the agreement, Incyte is providing compounds from its development portfolio, including retifanlimab, an anti-PD-1 monoclonal antibody, &hellip; Continue reading \"BriaCell Phase I\/IIa Clinical Trial Combination Study in Advanced Breast Cancer Patients Open for Enrollment\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-i-iia-clinical-trial-combination-study-in-advanced-breast-cancer-patients-open-for-enrollment\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-14T11:25:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MDAyOCM0Mjk2MDQ4IzIwOTA2NTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-i-iia-clinical-trial-combination-study-in-advanced-breast-cancer-patients-open-for-enrollment\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-i-iia-clinical-trial-combination-study-in-advanced-breast-cancer-patients-open-for-enrollment\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BriaCell Phase I\/IIa Clinical Trial Combination Study in Advanced Breast Cancer Patients Open for Enrollment","datePublished":"2021-07-14T11:25:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-i-iia-clinical-trial-combination-study-in-advanced-breast-cancer-patients-open-for-enrollment\/"},"wordCount":599,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-i-iia-clinical-trial-combination-study-in-advanced-breast-cancer-patients-open-for-enrollment\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MDAyOCM0Mjk2MDQ4IzIwOTA2NTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-i-iia-clinical-trial-combination-study-in-advanced-breast-cancer-patients-open-for-enrollment\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-i-iia-clinical-trial-combination-study-in-advanced-breast-cancer-patients-open-for-enrollment\/","name":"BriaCell Phase I\/IIa Clinical Trial Combination Study in Advanced Breast Cancer Patients Open for Enrollment - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-i-iia-clinical-trial-combination-study-in-advanced-breast-cancer-patients-open-for-enrollment\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-i-iia-clinical-trial-combination-study-in-advanced-breast-cancer-patients-open-for-enrollment\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MDAyOCM0Mjk2MDQ4IzIwOTA2NTg=","datePublished":"2021-07-14T11:25:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-i-iia-clinical-trial-combination-study-in-advanced-breast-cancer-patients-open-for-enrollment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-i-iia-clinical-trial-combination-study-in-advanced-breast-cancer-patients-open-for-enrollment\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-i-iia-clinical-trial-combination-study-in-advanced-breast-cancer-patients-open-for-enrollment\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MDAyOCM0Mjk2MDQ4IzIwOTA2NTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MDAyOCM0Mjk2MDQ4IzIwOTA2NTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-i-iia-clinical-trial-combination-study-in-advanced-breast-cancer-patients-open-for-enrollment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BriaCell Phase I\/IIa Clinical Trial Combination Study in Advanced Breast Cancer Patients Open for Enrollment"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/512810","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=512810"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/512810\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=512810"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=512810"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=512810"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}